Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan's U.K.-based subsidiary has introduced Rivastigmine Capsules POM, 1.5 mg, 3 mg, 4.5 mg and 6 mg to treat dementia in people with Alzheimer's disease.
Subscribe to our email newsletter
Rivastigmine Capsules are the generic forms of Novartis’ Exelon Capsules.
Mylan chairman and CEO Robert Coury said they are excited to be adding generic Rivastigmine to their portfolio of more than 350 products in the UK and delivering on their brand’s commitment of providing medicines to patients.